BTIG analyst Mark Massaro assumed coverage of Bionano Genomics with a Buy rating and $3.50 price target. The company is on a mission to transform the way the world sees the genome through optical genome mapping, and he believes that Bionano offers an elegant solution to accurately identify structural variation, SV, and changes in chromosomes, the analyst tells investors in a research note. Structural variation analysis could mark a new wave in genomics, as next-gen sequencers cannot reliably detect it, Massaro adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNGO:
- Multi-Center Research Study Illustrates How OGM Can Potentially Result in More Patients Qualifying for Treatments in Leukemia
- Bionano Genomics announces publication of study evaluating OGM for AML samples
- Bionano Genomics Announces American Society of Hematology (ASH) Annual Meeting Presentations Featuring OGM Utility Across Blood Cancer Research Applications
- Bionano Genomics to Acquire Purigen Biosystems to Enable Further Simplified and Accelerated DNA Isolation for Optical Genome Mapping (OGM) and Address Difficult Sample Types in New Applications with Isotachophoresis (ITP) on the Ionic Purification System
- Publication Shows Utility of OGM in Solid Tumor Research with Study on Detection of Complex Genomic Rearrangements in Prostate Cancer